FDA updates compliance guidelines on medical device website: Mandatory disclosure of clinical data and AI training sets

On May 9, 2026, the U.S. Food and Drug Administration (FDA) issued the "Digital Health Device Website Transparency Guidance", requiring Chinese suppliers of Class II and above medical devices sold to the U.S. market to prominently disclose on product pages of their English independent websites the source country of clinical validation data, the name of the original trial institution, as well as the composition of AI-assisted diagnostic model training datasets (including data region, sample size, and de-identification method). This requirement will be mandatorily enforced starting August 1, 2026, directly affecting the technical credibility assessment and compliance preparation pace of medical device companies expanding overseas, with clear practical implications for niche sectors such as digital health, AI medical devices, and cross-border medical device trade.

Event Overview

On May 9, 2026, the U.S. Food and Drug Administration (FDA) officially issued the "Digital Health Device Website Transparency Guidance". The guidance makes it clear that all Chinese manufacturers selling Class II and above medical devices in the U.S. market, if conducting product promotion or sales through their own English independent websites, must publicly disclose in a prominent position on the corresponding product pages three core pieces of information — the source country of clinical validation data, the full name of the institution conducting the original clinical trial, and the composition of the training dataset for any integrated AI-assisted diagnostic model, specifically including the geographic source of the training data, total sample size, and the data de-identification method used. This requirement will officially take effect on August 1, 2026 and be included within the scope of compliance review.

Which Segments Will Be Affected

Direct Trading Companies

These companies typically supply U.S. distributors, medical institutions, or DTC platforms under their own brands or through the ODM model, and operate English independent websites targeting overseas users. Because the guidance directly governs the independent website content of "Chinese suppliers of Class II and above medical devices sold to the U.S. market", the compliance of their product pages will directly affect downstream procurement decisions. The impact is mainly reflected in reduced responsiveness to customer due diligence, extended contract signing cycles, and lower webpage traffic conversion rates caused by incomplete information disclosure.

Manufacturing and Processing Companies (including licensed manufacturers)

As the registered entities actually holding FDA 510(k) or De Novo clearance, manufacturing companies must bear ultimate compliance responsibility for website disclosure content, even if the website is operated on their behalf by a brand owner or channel partner. The impact is concentrated in rising internal cross-department coordination pressure — the clinical department must provide traceable proof of trial institutions and data sources, the AI algorithm team must output structured training dataset metadata, and the legal and regulatory affairs departments must jointly review the boundaries of statements. Companies that have not established a data traceability documentation system will face the risk that disclosure content cannot be effectively implemented.

Channel Distribution Companies (including U.S. local distributors and importers)

Under current FDA regulations, importers within the United States (U.S. Agent / Importer of Record) have supervisory obligations regarding the compliance status of the products they represent. Although the new guidance does not directly govern their websites, if a distributor’s official website embeds links to the manufacturer’s product pages or reuses their content, it may also be regarded as "participating in product information presentation". The impact is reflected in the increased weighting of evaluating upstream suppliers’ disclosure capabilities, and some distributors have already begun to include "independent website transparency readiness" in their admission checklists for new partnerships.

What Related Companies or Practitioners Should Focus On and How to Respond Now

Prioritize Reviewing the Current Disclosure Status of Existing English Independent Website Product Pages

Check item by item against the original guidance text: whether a fixed module has been set up on Class II and above product pages, clearly indicating the country where the clinical trial was conducted, the full name of the CRO or hospital (not an abbreviation), the countries/regions covered by AI training data, the total sample size value (not a range), and the de-identification method (such as standard terms like k-anonymity and differential privacy). Avoid using vague expressions such as "multi-center" and "global multi-country collection".

Distinguish Between Policy Signals and Business Implementation Milestones

The guidance is a "guidance document" (Guidance), not a regulation (Regulation), but the FDA has clearly stated that it will include website disclosure status in postmarket surveillance and inspection focus areas. What deserves more attention at present is that after August 1, 2026, if a newly submitted 510(k) application includes an independent website link, FDA reviewers may proactively check the completeness of disclosures; if an existing product is selected for random inspection, it may also trigger a corrective action notice.

Simultaneously Update SEO Metadata and Structured Data

Schema.org markup (such as MedicalDevice and ClinicalTrial) needs to be added to the product page HTML to ensure that fields such as "funding", "studyLocation", and "datasetSize" can be recognized by search engines; long-tail English keywords such as "clinical data source" and "AI training dataset" should be naturally embedded in the page title (Title Tag) and description (Meta Description), balancing compliance disclosure and search visibility while avoiding fluctuations in historical rankings caused by page revisions.

Establish a Cross-Functional Disclosure Collaboration Mechanism

It is recommended that the regulatory affairs department take the lead, together with clinical affairs, AI algorithms, legal, and digital marketing teams, to form a quarterly update mechanism: key milestones such as changes in clinical trial institutions, iterative AI model upgrades, and data compliance audit results must synchronously trigger the website disclosure content revision process, with version records and approval trails retained for potential regulatory inquiries.

Editorial Viewpoint / Industry Observation

Observably, this guidance is not a standalone regulatory shift but a formalization of an emerging FDA expectation — transparency as infrastructure for digital health trust. It signals that website content is now treated as part of the device’s technical documentation ecosystem, rather than mere marketing material. Analysis shows the emphasis lies less on punitive enforcement and more on enabling downstream stakeholders (distributors, clinicians, payers) to assess evidence maturity at first touch. From industry perspective, it reflects a broader trend: regulatory agencies increasingly treating publicly accessible digital assets as extension points of compliance, especially where AI and real-world data are involved. The requirement is currently operational — not hypothetical — and its enforcement threshold appears tied to verifiability, not volume.

Conclusion: this guidance does not create entirely new compliance obligations, but extends existing clinical and AI data governance requirements to the public-facing digital interfaces of enterprises. Its core significance lies in pushing "verifiability" from internal regulatory documentation toward information nodes accessible in the international market. At present, it is more appropriately understood as a systematic stress test of the compliance maturity of medical device companies’ digital assets, rather than a simple content update task.

Information source notes:
Primary source: the "Digital Health Device Website Transparency Guidance" published on the official website of the U.S. Food and Drug Administration (FDA), with publication date of May 9, 2026.
Items to continue monitoring: whether the FDA will subsequently issue FAQs or sample templates on the specific presentation format of "prominent position" and "training dataset composition"; whether state-level healthcare procurement authorities will incorporate this disclosure requirement into supplier admission evaluation indicators.